CytoMed Therapeutics (GDTC) Cash & Equivalents (2021 - 2025)

CytoMed Therapeutics (GDTC) has disclosed Cash & Equivalents for 5 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 56.73% to $1.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Dec 2025, down 56.73% year-over-year, with the annual reading at $1.6 million for FY2025, 55.21% down from the prior year.
  • Cash & Equivalents hit $1.6 million in Q4 2025 for CytoMed Therapeutics, down from $3.7 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $6.7 million in Q4 2023 to a low of $1.1 million in Q4 2022.
  • Historically, Cash & Equivalents has averaged $3.0 million across 5 years, with a median of $1.9 million in 2021.
  • Biggest five-year swings in Cash & Equivalents: surged 485.32% in 2023 and later tumbled 56.73% in 2025.
  • Year by year, Cash & Equivalents stood at $1.9 million in 2021, then plummeted by 38.53% to $1.1 million in 2022, then soared by 485.32% to $6.7 million in 2023, then tumbled by 43.92% to $3.7 million in 2024, then plummeted by 56.73% to $1.6 million in 2025.
  • Business Quant data shows Cash & Equivalents for GDTC at $1.6 million in Q4 2025, $3.7 million in Q4 2024, and $6.7 million in Q4 2023.